O	0	11	Maintaining
O	12	18	normal
O	19	29	hemoglobin
O	30	36	levels
O	37	41	with
B-intervention	42	49	epoetin
I-intervention	50	54	alfa
O	55	57	in
O	58	64	mainly
B-eligibility	65	74	nonanemic
I-eligibility	75	83	patients
I-eligibility	84	88	with
I-eligibility	89	99	metastatic
I-eligibility	100	106	breast
I-eligibility	107	113	cancer
I-eligibility	114	123	receiving
I-eligibility	124	129	first
I-eligibility	129	130	-
I-eligibility	130	134	line
I-eligibility	135	147	chemotherapy
O	147	148	:
O	149	150	a
O	151	159	survival
O	160	165	study
O	165	166	.

O	167	169	To
O	170	178	evaluate
O	179	182	the
O	183	189	effect
O	190	192	on
O	193	201	survival
O	202	205	and
O	206	213	quality
O	214	216	of
O	217	221	life
O	222	224	of
O	225	236	maintaining
O	237	247	hemoglobin
O	248	249	(
O	249	251	Hb
O	251	252	)
O	253	255	in
O	256	259	the
O	260	265	range
O	266	268	of
O	269	271	12
O	272	274	to
O	275	277	14
O	278	279	g
O	279	280	/
O	280	282	dL
O	283	287	with
O	288	295	epoetin
O	296	300	alfa
O	301	307	versus
O	308	315	placebo
O	316	318	in
O	319	324	women
O	325	329	with
O	330	340	metastatic
O	341	347	breast
O	348	354	cancer
O	355	356	(
O	356	359	MBC
O	359	360	)
O	361	370	receiving
O	371	376	first
O	376	377	-
O	377	381	line
O	382	394	chemotherapy
O	394	395	.

O	396	404	Eligible
O	405	413	patients
O	414	418	were
O	419	427	randomly
O	428	436	assigned
O	437	439	to
O	440	447	receive
O	448	455	epoetin
O	456	460	alfa
O	461	463	40
O	463	464	,
O	464	467	000
O	468	469	U
O	470	474	once
O	475	481	weekly
O	482	484	or
B-control	485	492	placebo
O	493	496	for
O	497	499	12
O	500	506	months
O	506	507	.

O	508	513	Study
O	514	518	drug
O	519	522	was
O	523	532	initiated
O	533	535	if
O	536	544	baseline
O	545	547	Hb
O	548	551	was
O	552	553	<
O	554	556	or
O	557	558	=
O	559	561	13
O	562	563	g
O	563	564	/
O	564	566	dL
O	567	569	or
O	570	574	when
O	575	577	Hb
O	578	587	decreased
O	588	590	to
O	591	592	<
O	593	595	or
O	596	597	=
O	598	601	13g
O	601	602	/
O	602	604	dL
O	605	611	during
O	612	615	the
O	616	621	study
O	621	622	.

O	623	626	The
O	627	634	primary
O	635	638	end
O	639	644	point
O	645	648	was
B-outcome-Measure	649	651	12
I-outcome-Measure	651	652	-
I-outcome-Measure	652	657	month
I-outcome-Measure	658	665	overall
I-outcome-Measure	666	674	survival
I-outcome-Measure	675	676	(
I-outcome-Measure	676	678	OS
I-outcome-Measure	678	679	)
O	679	680	.

O	681	684	The
O	685	690	study
O	691	695	drug
O	696	710	administration
O	711	714	was
O	715	722	stopped
O	723	728	early
O	729	731	in
O	732	742	accordance
O	743	747	with
O	748	749	a
O	750	764	recommendation
O	765	769	from
O	770	773	the
O	774	785	Independent
O	786	790	Data
O	791	801	Monitoring
O	802	811	Committee
O	812	819	because
O	820	822	of
O	823	829	higher
O	830	839	mortality
O	840	842	in
O	843	846	the
O	847	852	group
O	853	860	treated
O	861	865	with
O	866	873	epoetin
O	874	878	alfa
O	878	879	.

O	880	890	Enrollment
O	891	894	had
O	895	899	been
O	900	909	completed
O	909	910	,
O	911	915	with
B-total-participants	916	919	939
O	920	928	patients
O	929	937	enrolled
O	938	939	(
O	939	946	epoetin
O	947	951	alfa
O	951	952	,
O	953	954	n
O	955	956	=
B-intervention-participants	957	960	469
O	960	961	;
O	962	969	placebo
O	969	970	,
O	971	972	n
O	973	974	=
B-control-participants	975	978	470
O	978	979	)
O	979	980	.

O	981	985	Most
O	986	994	patients
O	995	998	had
O	999	1001	Hb
O	1002	1006	more
O	1007	1011	than
O	1012	1014	12
O	1015	1016	g
O	1016	1017	/
O	1017	1019	dL
O	1020	1022	at
O	1023	1031	baseline
O	1032	1033	(
O	1033	1039	median
O	1040	1042	Hb
O	1042	1043	,
O	1044	1046	12
O	1046	1047	.
O	1047	1048	8
O	1049	1050	g
O	1050	1051	/
O	1051	1053	dL
O	1053	1054	)
O	1055	1057	or
O	1058	1064	during
O	1065	1068	the
O	1069	1074	study
O	1074	1075	.

O	1076	1080	From
O	1081	1084	the
O	1085	1090	final
O	1091	1099	analysis
O	1099	1100	,
B-outcome	1101	1103	12
I-outcome	1103	1104	-
I-outcome	1104	1109	month
I-outcome	1110	1112	OS
O	1113	1116	was
B-iv-bin-percent	1117	1119	70
I-iv-bin-percent	1119	1120	%
O	1121	1124	for
O	1125	1132	epoetin
O	1133	1137	alfa
O	1138	1148	recipients
O	1149	1152	and
B-cv-bin-percent	1153	1155	76
I-cv-bin-percent	1155	1156	%
O	1157	1160	for
O	1161	1168	placebo
O	1169	1179	recipients
O	1180	1181	(
O	1181	1182	P
O	1183	1184	=
O	1185	1186	.
O	1186	1188	01
O	1188	1189	)
O	1189	1190	.

B-outcome	1191	1198	Optimal
I-outcome	1199	1204	tumor
I-outcome	1205	1213	response
O	1214	1217	and
B-outcome	1218	1222	time
I-outcome	1223	1225	to
I-outcome	1226	1233	disease
I-outcome	1234	1245	progression
O	1246	1250	were
O	1251	1258	similar
O	1259	1266	between
O	1267	1273	groups
O	1273	1274	.

O	1275	1278	The
O	1279	1285	reason
O	1286	1289	for
O	1290	1293	the
O	1294	1304	difference
O	1305	1307	in
O	1308	1317	mortality
O	1318	1325	between
O	1326	1332	groups
O	1333	1338	could
O	1339	1342	not
O	1343	1345	be
O	1346	1356	determined
O	1357	1361	from
O	1362	1372	additional
O	1373	1383	subsequent
O	1384	1392	analyses
O	1393	1402	involving
O	1403	1407	both
O	1408	1413	study
O	1414	1418	data
O	1419	1422	and
O	1423	1428	chart
O	1429	1435	review
O	1435	1436	.

O	1437	1439	In
O	1440	1444	this
O	1445	1450	trial
O	1450	1451	,
O	1452	1455	the
O	1456	1459	use
O	1460	1462	of
O	1463	1470	epoetin
O	1471	1475	alfa
O	1476	1478	to
O	1479	1487	maintain
O	1488	1492	high
O	1493	1495	Hb
O	1496	1503	targets
O	1504	1506	in
O	1507	1512	women
O	1513	1517	with
O	1518	1521	MBC
O	1521	1522	,
O	1523	1527	most
O	1528	1530	of
O	1531	1535	whom
O	1536	1539	did
O	1540	1543	not
O	1544	1548	have
O	1549	1555	anemia
O	1556	1558	at
O	1559	1562	the
O	1563	1568	start
O	1569	1571	of
O	1572	1581	treatment
O	1581	1582	,
O	1583	1586	was
O	1587	1597	associated
O	1598	1602	with
O	1603	1612	decreased
O	1613	1621	survival
O	1621	1622	.

O	1623	1633	Additional
O	1634	1642	research
O	1643	1645	is
O	1646	1654	required
O	1655	1657	to
O	1658	1665	clarify
O	1666	1669	the
O	1670	1679	potential
O	1680	1686	impact
O	1687	1689	of
O	1690	1704	erythropoietic
O	1705	1711	agents
O	1712	1714	on
O	1715	1723	survival
O	1724	1728	when
O	1729	1732	the
O	1733	1735	Hb
O	1736	1742	target
O	1743	1748	range
O	1749	1751	is
O	1752	1754	10
O	1755	1757	to
O	1758	1760	12
O	1761	1762	g
O	1762	1763	/
O	1763	1765	dL
O	1765	1766	.
